The points you raise go the core or root of IMU's problems. On a...

The points you raise go the core or root of IMU's problems. On a day when the stock ought gain traction it hemorrhages close to 7%. Not good.

The NWR Media ASX Announcement formula adopted by Imugene clearly isn't working, and hasn't for some time. Those following other biotechs are used now to more succinct announcements pertaining to clinical trials with respect to patient dosed numbers, ETA dates for forthcoming clinical trial results and the composition of future trial participants, along with their expected outcomes post treatment, based on preclinical and past results. Third party opinions from experts are sometimes proffered, in addition to relevant market segment information, be it from recent market research or current industry figures.

Once again with Imugene there is still some smoke and mirrors. The company is happy to announce the enrolled sites and to state what their drug being trialled aims to combat. But no specifics or timelines are afforded investors, from which to place on their fridge calendars as a given. Hence the let down following Leslie Chongs post OASIS Announcement interview today, which once again failed to engender any meaningful shareholder response, other than further selling. At times such as these investors start to recite phrases such as, "We've heard it all before." Many are starting to ask the same old questions and make the same old remarks, such as "The science all sounds good, but is the trial and testing even going to reach its fruition, let alone deliver the much anticipated results?"

Whether we like it or not, @Ragnarolf, the questions you ask, be they valid or presumptuous, are similar to those being asked behind closed doors by shareholders deciding whether to remain on the IMU register, or potentially attain greater capital gains elsewhere. It's clearly up to Imugene to create a stronger value proposition than competing interests, whose modus operandi is to attract prospective shareholders from stocks such as Imugene (IMU - ASX). Imugene (IMU- ASX) have clearly not been up to the task in years of late, as exemplified by the crumbling IMU share price, in contrast to those cut from a similar cloth.

For those invested in the IMU Story, best of luck in the weeks ahead. Let's hope the IMU train starts to gain some windspeed and momentum on the way home in 2024.

Opinions only WMHB